Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

NCT01534897 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01534897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01534897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
Lead sponsor
Massachusetts General Hospital
Phase
Not applicable
Overall status
Completed
Start date
July 31, 2012
Completion date
March 31, 2014
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

papillary thyroid carcinoma